Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Current Deferred Revenue (2016 - 2025)

Sangamo Therapeutics has reported Current Deferred Revenue over the past 16 years, most recently at $899000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $899000.0 for Q4 2025, down 88.1% from a year ago — trailing twelve months through Dec 2025 was $899000.0 (down 88.1% YoY), and the annual figure for FY2025 was $899000.0, down 88.1%.
  • Current Deferred Revenue for Q4 2025 was $899000.0 at Sangamo Therapeutics, down from $7.6 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for SGMO hit a ceiling of $94.4 million in Q1 2021 and a floor of $774000.0 in Q3 2024.
  • Median Current Deferred Revenue over the past 5 years was $9.6 million (2023), compared with a mean of $41.0 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 97.93% in 2023 and later soared 876.23% in 2025.
  • Sangamo Therapeutics' Current Deferred Revenue stood at $85.7 million in 2021, then tumbled by 39.59% to $51.8 million in 2022, then crashed by 97.13% to $1.5 million in 2023, then soared by 408.82% to $7.6 million in 2024, then crashed by 88.1% to $899000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $899000.0 (Q4 2025), $7.6 million (Q3 2025), and $7.6 million (Q2 2025) per Business Quant data.